John Chen is a Neurology physician. ClinicalTrials.gov lists 8 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
2617 E Chapman Ave Ste 101
Orange, CA 928693251
Telephone
714-202-0218Provider last certified this registry record 20 Nov 2025.
Clinical trials
- Ablation of Arteries for the Treatment of Type 2 Diabetes Mellitus and Its Comorbidities
Sponsor: Neurotronic, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
51 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- UCB, Inc.Program year202515 payments
- Grifols USA, LLCProgram year202512 payments
- ABBVIE INC.Program year202511 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
86.8%Gabapentinoids13%Gabapentin84%Pregabalin16%Part D≥72 patientsOther antiepileptics12.3%Levetiracetam36%Lacosamide25%Topiramate19%Xcopri7%Epidiolex5%Vimpat4%Keppra Xr4%Part D<11 patients+ 21 more classes in this area
Blood & clotting
5.2%P2Y12 inhibitor2.9%Clopidogrel100%Part D≥20 patientsFactor Xa inhibitor1.2%Eliquis100%Part D<11 patients+ 2 more classes in this area
Cardiovascular
5.1%Statin3.3%Atorvastatin Calcium82%Rosuvastatin Calcium18%Part D<11 patientsBeta blocker1.2%Propranolol Hcl57%Metoprolol Tartrate43%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”